language_icon
EN
HI

Granules India Share price

GRANULES

655.7

4.70 (0.72%)
NSE
BSE
Last updated on 17 Apr, 2026 | 15:52 IST
Today's High

660.50

Today's Low

646.85

52 Week Low

430.70

52 Week High

660.50

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Granules India Chart

Granules India Share Key Metrics

Volume
10.93 L
Market Cap
16248.04 CR
LTQ@LTP
2@655.70
ATP
654.67
Var Margin
17.28 %
Circuit Range
520.8-781.2
Delivery %
41.99 %
Value
71.55 CR
ASM/GSM
No
Market Lot
1

Summary

Granules India share price stands at ₹655.7 at 17 Apr, 2026 | 15:52. The stock Granules India intraday movement has stayed between ₹646.85 and ₹660.50, while on a 52-week basis it has fluctuated from ₹430.70 to ₹660.50.
In terms of trading activity, Granules India has recorded a volume of 1092875 shares. The Granules India has a market cap of ₹247796921. The stock’s Average Traded Price (ATP) stands at ₹65467, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 2, 65570.
The Granules India operates within a circuit range of ₹520.8-781.2 – ₹520.8-781.2, with a Value of ₹71.55 CR. The Delivery Percentage for the day is 41.99%. Additionally, Granules India currently falls under the No framework, and trades with a market lot size of 1.

Granules India Fundamentals

View More
P/E Ratio

29.56

P/B Ratio

3.64

Div. Yield

0.23

Sector P/E

64.08

Sector P/B

3.47

Sec. Div. Yield

0.57

Granules India Resistance and Support

Pivot 647.68

Resistance

First Resistance

659.31

Second Resistance

667.63

Third Resistance

679.26

Support

First Support

639.36

Second Support

627.73

Third Support

619.41

Granules India Shareholding Pattern

View More
  • 2016-17
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

38.02%

Mutual Fund

2.85%

Insurance

10.4%

Foreign Institutional Investors

15.31%

Domestic Institutional Investors

3.76%

Retail

29.67%

Others

-0.01%

Total Promoters
MAR '26
38.02%

Granules India Corporate Actions

DateAgenda
2026-01-23Quarterly Results
2025-11-13Quarterly Results
2025-08-12Quarterly Results
2025-05-28Audited Results & Final Dividend
2025-01-24Quarterly Results

Granules India News

Granules India Ltd-$ - 532482 - Board Meeting Intimation for Inter-Alia, To Consider And Approve The Audited Financial Results For The Fourth Quarter And Financial Year Ended On March 31, 2026 And The Recommendation Of Final Dividend For FY 2025-26, If Any.

Granules India's board is scheduled to meet on April 29, 2026. The agenda includes considering and approving the audited financial results for the fourth quarter and full fiscal year 2026, along with a recommendation for a final dividend.
Apr 16 2026 11:04:00

Granules India Ltd-$ - 532482 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Granules India Limited's Chantilly, US site completed a US FDA cGMP audit with four Form 483 observations. These observations are related to procedural matters, with no data integrity issues reported. The company is committed to addressing them within stipulated timelines.
Apr 04 2026 15:04:00

Granules India Limited

Granules India's US subsidiary, Granules Pharmaceuticals, completed a routine US FDA cGMP audit at its Chantilly, Virginia site. The audit found four procedural Form 483 observations but no data integrity issues. The company commits to address these within stipulated timelines.
Apr 04 2026 15:04:00

Granules India Limited

Granules India's promoter, Dr. Krishna Prasad Chigurupati, declared that no new encumbrance has been made on the company's shares during the financial year ended March 31, 2026, other than those already disclosed. This ensures transparency regarding promoter shareholdings.
Apr 02 2026 18:04:00

Granules India Ltd-$ - 532482 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Granules Life Sciences, a subsidiary of Granules India, received a Voluntary Action Indicated (VAI) classification from the US FDA for its Shamirpet manufacturing facility. The inspection, conducted between December 15 and 19, 2025, for cGMP and PAI of oral solid dosage operations, concluded with no regulatory action recommended, bolstering its finished dosage manufacturing capabilities.
Mar 31 2026 11:03:00
Read More

About Granules India

NSE : 11872  
BSE : 532482  
ISIN : INE101D01020  

Granules India Ltd (GIL) was incorporated as a PrivateLimited Company on March 16 1991 and was later convertedinto a Public Limited Company on February 8 1993. GILcommenced its operations in April 1991 as a merchantexporter of bulk drugs like Paracetamol Guaifenesin andChloro Pheniramine Maleste. It has been exporting mainlyto the developed markets such as U.S.A. Europe Mexico andHongkong. Since 1992 GIL concentrated on export ofParacetamol powder which was procured from a GroupCompany M/s.Triton Laboratories Pvt Ltd (TLPL) a smallscale unit. In 1993-94 the international prices of bulkdrugs like Paracetamol were under pressure and GIL decidedto enter into value added areas.In April 1993 GIL also joined as a partner of M/s.TritonLaboratories (TL) a partnership firm promoted by thepromoters in 1985. After GIL became a partner. TL crestedfacilities for manufacture of DC blends of Paracetamol anddirectly entered into its export market. Later TL decidedto diversify into manufacturing of bulk drugs and startedimplementing a project for the same. In August 1994 aspart of consolidation and restructuring the Group''soperations. TL was dissolved and its assets andliabilities were taken over by GIL at book value. The assetswere independently valued by Shri S.Deshpande CharteredEngineer and approved valuer. (Rs.lakhs)Description Book Transfer Chartered value value Engineer''s valuationAssetsLand & Development *35.54 35.54 39.58Building 22.42 22.42 # 102.57Plant & Machinery 13.36 13.36) # 125.10Others 17.76 17.76)Capital work-in-progress 174.17 174.17 263.25 267.25 Investment 5.00 5.00Total (A) 268.25LiabilitiesNet current liabilities 63.27 63.27Long term liabilities 0.92 0.92Total liabilities (B) 64.19Purchase consideration (A) - (B) 204.06* The value of land purchased in 1985 for Rs.88994 wasrevalued at Rs.2826980/- on March 30 1993 at Government fixed rate of Rs.500/-per sq. yard and as valued by M/s. M. Raja Rao & Co.Chartered Engineers. Registered valuers & Insurancesurveyors. Development cost includes land leveling. # Includes Capital work-in-progressOut of the purchase consideration of Rs.204.06 lakhs theshares of the partners were as follows: - GIL - Rs.131.13 lakhs Sri Krishna Prasad - Rs. 37.47 lakhs Smt C. Uma Devi - Rs. 35.45 lakhsSri Krishna Prasad and Smt C. Uma Devi were allotted374700 and 354500 equity shares respectively of GIL ofRs. 10/- each at par in settlement of their share ofpartnership as detailed above. In addition to the above GILallotted (I) 6500 equity shares of Rs. 10/- each at par toSmt. C. Uma Devi in settlement-of rental dues for theyears 1992-93 and 1993-94 and (ii) 2600 equity shares toDr. C. Hariprasad 1500 equity shares to Dr. C. Nageswara Rao and 5000 equity shares to Smt R.Santisree all these of Rs. 10/- each and issued at partowards the long term liabilities taken over from thepartnership firm as detailed above.GIL has also purchased the assets of a sick unit from theAndhra Pradesh State Financial Corporation (APSFC) on March 30 1994. This unit was manufacturing bulk drugs.The assets comprising of land buildings and plant andmachinery were purchased for Rs.35 lakhs by availing termloan from APSFC (Rs.22.75 lakhs) and own funds (Rs.12.25lakhs). These assets are not presently used and areearmarked for future expansion needs of the companyGIL is now implementing the ongoing project taken over fromTL and is exporting DC blends of Paracetamol ofinternational pharmacopial standards from September 11994. Trial production of Folic Acid commenced in November1994 and commercial production in August 1995. The list of GIL''s clients include M/s.Roussel CorporationHelm New York Chemical Corporation and Granutec all ofU.S.A Welding GMBH & Co of Germany and Flavine Espana S.A.of Spain.

Read More

Granules India Management

NamePosition
Dr. Krishna Prasad Chigurupati Chairman & Managing Director
Dr. K V S Ram Rao Joint Managing Director & CEO
View More

Granules India FAQs

The Buying Price of Granules India share is 655.7 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Granules India stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Granules India, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Granules India shares is 29.56. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Granules India shares is 3.64. Useful to assess the stock's value relative to its book value.

To assess Granules India’s valuation compare Sector P/E, P/B which are 64.08 & 3.47 with sector averages, along with growth rates and financial metrics.

The Market Cap of Granules India is 16248.04 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Granules India share price is 660.50 & 430.70. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Granules India belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost